CLINICAL TRIALS PROFILE FOR DINUTUXIMAB

All Clinical Trials for dinutuximab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00026312 ↗	Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2001-10-18	This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
NCT01041638 ↗	Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma	Completed	National Cancer Institute (NCI)	Phase 3	2009-12-21	This phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18, may find tumor cells and help kill them. Colony-stimulating factors, such as sargramostim, may increase the number of immune cells found in bone marrow or peripheral blood. Aldesleukin may stimulate the white blood cells to kill tumor cells. Isotretinoin may help neuroblastoma cells become more like normal cells, and to grow and spread more slowly. Giving monoclonal antibody Ch14.18 with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant may be an effective treatment for neuroblastoma.
NCT01704716 ↗	High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)	Recruiting	St. Anna Kinderkrebsforschung	Phase 3	2002-02-01	This is a randomized study of the European SIOP Neuroblastoma Group (SIOPEN) in high-risk neuroblastoma (stages 2, 3, 4 and 4s MYCN-amplified neuroblastoma, stage 4 MYCN non amplified > 12 months at diagnosis). The protocol consists of a rapid, dose intensive induction chemotherapy, peripheral blood stem cell harvest, attempted complete excision of the primary tumour, myeloablative therapy followed by peripheral blood stem cell rescue, radiotherapy to the site of the primary tumour and immunotherapy (R4 randomization - isotretinoin and ch14.18/CHO (Dinutuximab beta, Qarziba ®).), with or without s.c. aldesleukin (IL-2)). Patients diagnosed after the closure of R3 randomization will not be R4 randomized. For these patients the use of ch14.18/CHO antibody is recommended without scIL-2 as continuous infusion as standard of care outside of controlled trials. ch14.18/CHO received marketing authorization by EMA in May 2017 (Qarziba ®). In the induction phase, all patients receive Rapid COJEC following the result of the R3 randomization which was closed on June 8th, 2017 after inclusion of 630 patients as planned. Following induction treatment peripheral blood stem cell harvest (PBSCH) is performed and complete excision of the primary tumour will be attempted. Patients with an inadequate metastatic response to allow BuMel MAT followed by PBSCR at the end of induction should receive 2 TVD (Topotecan, Vincristine, Doxorubicin) cycles. After Rapid COJEC induction, localized patients will proceed to consolidation. Patients aged 12-18 months at diagnosis, with stage 4 neuroblastoma, no MYCN amplification and without segmental chromosomal alterations (SCAs) are thought to have a good prognosis and will stop treatment after induction therapy and surgery to the primary tumour. Consolidation consists of BuMel MAT based on the results of the R1 randomization followed by peripheral blood stem cell rescue (PBSCR) and radiotherapy to the site of the primary tumour. The R2 immunotherapy randomization using ch14.18/CHO as 8 hour infusion on 5 consecutive days ( total dose (100mg/m²) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) is closed. The amended R4 immunotherapy randomization using ch14.18/CHO as continuous infusion (total dose 100mg/m² over 10 days) with or without aldesleukin (IL-2) alternated with isotretinoin (13-cis-RA) has accrued according to plan with results pending awaiting data maturity and DMC approval.
NCT01711554 ↗	Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2013-02-04	This phase I trial studies the side effects and best dose of lenalidomide when given together with dinutuximab with or without isotretinoin in treating younger patients with neuroblastoma that does not respond to treatment or that has come back. Drugs used in chemotherapy, such as lenalidomide and isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may interfere with the ability of tumor cells to grow and spread. Giving more than one drug (combination chemotherapy) together with dinutuximab therapy may kill more tumor cells.

Clinical Trial Conditions for dinutuximab

Condition Name

Condition Name for dinutuximab
Intervention	Trials
Neuroblastoma	16
Recurrent Neuroblastoma	5
Ganglioneuroblastoma	5
High Risk Neuroblastoma	4

Condition MeSH

Condition MeSH for dinutuximab
Intervention	Trials
Neuroblastoma	27
Ganglioneuroblastoma	7
Osteosarcoma	1
Leiomyosarcoma	1

Clinical Trial Locations for dinutuximab

Trials by Country

Trials by Country for dinutuximab
Location	Trials
United States	358
Canada	32
Australia	25
Spain	9
New Zealand	9

Trials by US State

Trials by US State for dinutuximab
Location	Trials
California	16
Pennsylvania	15
Texas	14
Ohio	14
Michigan	13

Clinical Trial Progress for dinutuximab

Clinical Trial Phase

Clinical Trial Phase for dinutuximab
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	3
PHASE1	4

Clinical Trial Status

Clinical Trial Status for dinutuximab
Clinical Trial Phase	Trials
Recruiting	13
Active, not recruiting	7
Not yet recruiting	4

Clinical Trial Sponsors for dinutuximab

Sponsor Name

Sponsor Name for dinutuximab
Sponsor	Trials
National Cancer Institute (NCI)	10
United Therapeutics	8
New Approaches to Neuroblastoma Therapy Consortium	4

Sponsor Type

Sponsor Type for dinutuximab
Sponsor	Trials
Other	37
Industry	14
NIH	10

Dinutuximab: Clinical Trials Update and Market Outlook

Last updated: May 5, 2026

What is dinutuximab and what label does it cover?

Dinutuximab is an anti-GD2 monoclonal antibody used with GM-CSF and IL-2 for patients with high-risk neuroblastoma and with additional regimen components depending on line of therapy and trial protocol.

Core commercial product(s)

• dinutuximab (US approval history tied to ch14.18/CHO-based anti-GD2): marketed as Dinutuximab (Unituxin) in the US for high-risk neuroblastoma.
• dinutuximab beta (as used in Europe and some global trials): a related anti-GD2 antibody format used in EMA-era indications and studies; data streams for “dinutuximab beta” frequently map to the same clinical program logic around GD2 targeting.

Regimen mechanics that drive utilization

• GD2-directed antibody plus cytokines (commonly GM-CSF and IL-2) and other supportive meds (pain control, anti-hypersensitivity) are part of standard-of-care approaches in high-risk neuroblastoma treatment pathways.
• Utilization is concentrated in pediatric oncology centers with neuroblastoma expertise and established protocol-driven care.

Which clinical trials are most likely to move dinutuximab’s future?

Publicly traded market impact comes from three buckets: (1) label expansion (new lines, combinations, or geographies), (2) competitor differentiation (safety, logistics, or response rates), and (3) durable survival benefit confirmation in controlled settings.

1) Maintenance / consolidation in high-risk neuroblastoma (GD2 antibody backbone)

Dinutuximab and dinutuximab beta anchor GD2 antibody therapy strategies in high-risk neuroblastoma after intensive induction and transplant. Trial updates typically track:

• Event-free survival (EFS)
• Overall survival (OS)
• Toxicity burden (notably capillary leak syndrome, infusion reactions, neuropathic pain, and need for analgesia)
• Treatment delivery feasibility (hospital time, infusion schedule, outpatient vs inpatient)

Why this matters for investment case The GD2 antibody class has a fixed treatment window in many protocols. Even small changes in:

• eligible population size (risk stratification),
• timing (consolidation vs later maintenance),
• and regimen simplification, can change total addressable demand.

2) Combination strategies with checkpoint inhibition and other agents

Dinutuximab’s development logic overlaps with combination work pairing GD2 antibodies with:

• immune checkpoint inhibitors (to deepen T-cell mediated activity),
• kinase inhibitors or immunomodulators,
• and agents that modulate the tumor microenvironment.

Market signal to track

• Whether combinations show additional OS/EFS benefit over GD2 alone.
• Whether safety profiles stay within tolerability for pediatric patients.
• Whether response rates justify additional cycles or new lines.

3) Biosimilar and next-gen GD2 antibodies

The market will also react to:

• biosimilar approvals or launch-readiness for dinutuximab/dinutuximab beta molecules,
• and next-generation GD2 antibodies or bispecific constructs that aim to improve safety or efficacy.

Key commercial driver Any credible competitive entry that reduces cost per treated patient or improves outpatient manageability pressures unit pricing and formulary access.

Where does dinutuximab sit in the competitive landscape?

Dinutuximab faces competition primarily from other anti-GD2 products and from evolving neuroblastoma treatment standards. The competitive set is shaped by:

• antibody format (chimeric vs humanized),
• cytokine regimen requirements,
• and adverse event management requirements.

Competitive dimensions that decide market share

Dimension	What typically shifts demand	Commercial implication
Safety and pain management	Lower incidence or shorter duration of severe pain/capillary leak	Faster adoption and fewer delays in dosing schedules
Treatment logistics	Reduced inpatient time or simplified infusion protocol	Lower provider burden in high-throughput centers
Efficacy endpoints	Better EFS/OS in a defined population	Replaces other regimens and becomes default backbone
Drug availability and pricing	Reduced cost or stable supply	Wins tender and payer preference

What is the clinical trial update cadence and what should be treated as “market-moving”?

For dinutuximab, the market moves when updates hit one of these triggers:

1. Regulatory filings based on randomized survival data (EFS/OS).
2. New combination protocol outcomes with a clear safety profile that supports broader use.
3. Biosimilar or competitive product launches that show differentiated cost or administration benefits.

In practice, hospital procurement is driven by:

• whether clinicians can deliver the regimen within their standard neuroblastoma care workflow, and
• whether patients qualify under the payer and clinical eligibility criteria.

Market analysis: How big is the opportunity and who buys?

Demand formation

Dinutuximab demand correlates to:

• the incidence of high-risk neuroblastoma requiring intensive therapy and consolidation/maintenance schedules,
• the fraction of patients who complete protocolized GD2 antibody therapy,
• and the geographic uptake and reimbursement coverage across major pediatric oncology markets.

Buyer profile

• US: pediatric oncology centers with established high-risk neuroblastoma pathways under pediatric oncology networks.
• EU and UK: specialized centers following EMA-aligned prescribing and reimbursement frameworks.
• Emerging markets: low-to-mid adoption where GD2 access is constrained by pricing, hospital infrastructure, and availability.

Revenue drivers

Driver	Directional impact on dinutuximab	Mechanism
Survival benefit confirmation	Positive	Converts guideline adoption and expands eligible population
Toxicity management improvements	Positive	Increases completion rates and dose delivery
Competitive entry or biosimilar launch	Negative	Price compression and switching
Cytokine regimen complexity	Negative	Higher administrative burden and higher barrier to non-core centers

Pricing and reimbursement: what moves unit economics?

While exact net pricing varies by contract, the commercial economics of anti-GD2 antibodies hinge on:

• total number of cycles and dosing schedule,
• whether the regimen requires inpatient stays vs outpatient infusion,
• payer coverage and prior authorization duration,
• and total cost of supportive care (analgesia, antihypersensitives, ICU-level supportive management when required).

In high-value markets, formulary decisions respond to:

• “total episode cost” (drug plus administration plus supportive care), and
• evidence of reduced severe adverse events that drive length of stay and resource utilization.

Forecast: What is the market projection for dinutuximab (2026 to 2031)?

This projection is based on three market forces that typically dominate in pediatric oncology monoclonal antibody categories:

1. Guideline durability for GD2 antibody backbone in high-risk neuroblastoma.
2. Competitive pressure from other anti-GD2 products and potential biosimilars.
3. Efficacy and safety evidence flow from ongoing trials and combination studies.

Base case (2026-2031): gradual revenue pressure with maintained core demand

• Dinutuximab retains a stable core share in high-risk neuroblastoma where GD2 antibody backbone is standard.
• Revenue growth is limited by:
  • fixed eligible population size (incidence and high-risk proportion),
  • and competitive or pricing pressure over time.

Implication The base case resembles a “volume-stable, price-down” model, where any label expansion offsets modest unit price compression.

Bull case: label expansion or better tolerability enables higher completion rates

• If combination trials or refined supportive care improve EFS/OS outcomes or reduce severe toxicity, dinutuximab demand rises through higher completion rates and expanded adoption by non-core centers.
• Growth accelerates if new protocols broaden the eligible population beyond current practice patterns.

Implication Revenue growth increases through both volume uplift (more patients treated) and improved episode completion.

Bear case: competition and biosimilar dynamics compress price faster than protocol expansion

• Entry of competitors with simplified administration or improved safety drives switching.
• If biosimilars or next-gen GD2 products capture payer and center preference, dinutuximab faces margin compression.

Implication Revenue declines become more visible, first in pricing and then in share as protocols shift.

Key risks that can change the projection

Clinical and operational

• High incidence of treatment-related toxicities can limit completion rates and increase supportive care costs.
• Any safety signal in combination strategies can slow adoption.
• Protocol changes that alter dosing schedules can reduce average units per patient.

Competitive

• Next-gen anti-GD2 products with differentiated administration or improved tolerability.
• Biosimilars with cost advantages and stable supply.

Commercial

• Payer scrutiny focused on cost-effectiveness and total episode cost.
• Hospital procurement constraints and the administrative burden of complex regimens.

How should an R&D or investment decision use this update?

Actionable business read-through

1. Treat dinutuximab as a core backbone asset in high-risk neuroblastoma where GD2 antibody therapy remains standard, until randomized data or guideline changes remove it.
2. Model the forecast as “core demand minus pricing and share pressure.” Competition and administration complexity drive downside.
3. Watch for changes in supportive care standards that increase dosing completion rates. This can outperform “headline efficacy” on near-term demand.

Key Takeaways

• Dinutuximab is a GD2 antibody backbone therapy in high-risk neuroblastoma, with demand concentrated in specialized pediatric oncology centers.
• Market evolution depends on survival and safety evidence, especially around combination protocols and regimen delivery (pain and capillary leak management).
• The 2026-2031 trajectory is most likely a core-demand preservation with gradual pricing and share pressure as competing anti-GD2 options and potential biosimilar dynamics strengthen.
• The biggest swing factors are (i) label expansion or broader protocol adoption and (ii) competitive differentiation in tolerability and treatment logistics.

FAQs

1. What patient population drives dinutuximab sales?
   Patients with high-risk neuroblastoma receiving protocolized anti-GD2 therapy, typically in consolidation or maintenance settings after intensive initial treatment.

2. What clinical endpoints are most important for dinutuximab’s market outlook?
   EFS and OS for survival impact, plus toxicity metrics tied to infusion reactions, capillary leak, and pain-related outcomes that affect treatment completion.

3. How does competition affect dinutuximab’s pricing power?
   Competitive anti-GD2 products and biosimilar entry can pressure net price via payer and center preference shifts, especially if they offer simpler administration or improved tolerability.

4. What operational factor can change demand quickly?
   Treatment delivery feasibility, including inpatient vs outpatient logistics and the ability to manage adverse events without delaying dosing.

5. Where do market opportunities come from?
   Through expanded eligible populations, improved completion rates via supportive care optimization, and any combination regimens that add measurable benefit over GD2 antibody backbone therapy.

---

References

[1] FDA. Unituxin (dinutuximab) Prescribing Information. U.S. Food and Drug Administration.
[2] EMA. Assessment history and product information for dinutuximab beta and anti-GD2 medicines in neuroblastoma. European Medicines Agency.
[3] NCI. Neuroblastoma treatment protocols and guideline-relevant background on GD2-targeted immunotherapy. National Cancer Institute.
[4] Published clinical trial reports and oncology congress publications covering anti-GD2 regimens in high-risk neuroblastoma (EFS/OS and toxicity outcomes).